www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

November 13, 2018

PDF Version

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions:

1.Details of the person discharging managerial responsibility / person closely associated
a)NameSøren Daniel Niegel
2.Reason for the notification
a)Position/statusMember of the Board of Management
b)Initial notification/amendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameALK-Abelló A/S
b)LEI529900SGCREUZCZ7P020
4.Details of the transaction(s): section to be repeated for (i) each type of instrument: (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have been conducted
a)


Description of the financial instrument, type of instrument

Identification code
Share options

DK0060027142
b)Nature of the transactionPurchase (exercise of share options)
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 3,045,770  7,000
d)


Aggregated information
- Aggregated volume
- Price
7,000
DKK 3,045,770
e)Date of the transaction2018-11-12
f)Place of the transactionNASDAQ Copenhagen

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525

Attachment

  • FM_13_18UK_13112018
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved